New drug-resistant tuberculosis patients and other new drugs come out

Medical Network August 20th After more than 40 years of drug-free dilemma, the new drug "Beta quinoline" for multidrug-resistant tuberculosis, approved by the China Food and Drug Administration to carry out three phase clinical trials in China. A few days ago, in the Wuhan Pulmonary Hospital (City Tuberculosis Control Institute), Mr. Zhang, a patient in his 30s, became the first beneficiary.

Multidrug-resistant tuberculosis refers to resistance to both first-line anti-tuberculosis drugs, "isoniazid" and "rifampicin". At present, there are 600,000 new patients with MDR-TB in the world, and China accounts for 1/4 of the total, and the number of cases is the second. Compared with common tuberculosis, multidrug-resistant tuberculosis is complicated to diagnose and difficult to treat, and is called "infectious cancer." The patient has a treatment period of up to 24 months and costs more than $100,000. If further developed into extensive resistance, there is almost no cure, and patients can only wait for death.

Wang Weihua, secretary of the Party Committee of Wuhan Pulmonary Hospital, said that due to the high cost of research and development of new drugs, the research and development of anti-tuberculosis drugs is far from keeping pace. The widely used "Rifampin" appeared in the 1970s and has not been used for 40 years. New drugs are available. In December 2012, the new anti-tuberculosis drug “Betaquinoline” developed by Johnson & Johnson in the United States was launched. At the end of November 2016, the drug was approved by the State Food and Drug Administration of China and passed the “Anti-TB New Drug Introduction and Protection Mechanism Project” ( referred to as "NDIP" project), is provided in the form of donations to the use of Chinese patients with lung hospital in Wuhan to become one of 16 pilot units nationwide, it is the only one in Hubei Province.

At 11:30 on the morning of August 13, Wang Weihua, secretary of the party committee of the hospital, personally handed the "Beta quinoline" bearing the hope of patients with multidrug resistance to the first patient of the project in Hubei Province. This not only means that Hubei tuberculosis patients will have a new means of fighting multidrug-resistant tuberculosis in the future, but also bring new hope for rehabilitation. (Reporter Wu Ye correspondent Gong Yu Wang Jianjie)